Here's Why Johnson & Johnson's Vaccine Could Overtake Both Pfizer and Moderna

[cafead]

via

• Johnson & Johnson's vaccine won't capture nearly as much market share as Pfizer and Moderna this year.
• The company's vaccine has been at a disadvantage due to a perceived lower efficacy rate.
• Its effectiveness against the delta variant could lead to an increase in demand. But is the stock a buy?

article source